Literature DB >> 33708914

Development and validation of nomograms for predicting blood loss in placenta previa with placenta increta or percreta.

Ruihui Lu1, Ran Chu1, Na Gao1, Guiyang Li1, Haiyang Tang1, Xinxin Zhou1, Xiangxin Lan1, Shuyi Li1,2, Xi Zhang1, Yintao Xu1, Yuyan Ma1.   

Abstract

BACKGROUND: To develop the risk prediction model of intraoperative massive blood loss in placenta previa with placenta increta or percreta.
METHODS: This study included 260 patients, of whom 179 were allocated to the development group and 81 to the validation group. Univariate and multivariate logistic regression analyses were used to identify characteristics that were associated with massive blood loss (≥2,500 mL) during cesarean section. A nomogram was constructed based on regression coefficients. Receiver-operating characteristic curve, calibration curve, and decision curve analyses were applied to assess the discrimination, calibration, and performance of the model.
RESULTS: Two models were constructed. The preoperative feature model (model A) consisted of vascular lacunae within the placenta and hypervascularity of the uterine-placental margin, uterine serosa-bladder wall interface, and cervix. The preoperative and surgical feature model (model B) consisted of an emergency cesarean section, no preoperative balloon placement of the abdominal aorta, and the previously mentioned four ultrasound signs. Model B had better discrimination than model A (area under the curve: development group: 0.839 vs. 0.732; validation group: 0.829 vs. 0.736). Model B showed a higher area under the decision curve than model A in both the training and validation groups.
CONCLUSIONS: The preoperative and surgical feature model for placenta previa with placenta increta or percreta can improve the early identification and management of patients who are at high risk of intraoperative massive blood loss. 2021 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Placenta previa; intraoperative massive blood loss; placenta increta; placenta percreta; risk prediction model

Year:  2021        PMID: 33708914      PMCID: PMC7944278          DOI: 10.21037/atm-20-5160

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

Over the past 2 decades, several epidemiological studies have shown a direct association between a previous cesarean section and an increased risk of placenta previa and placenta increta or percreta in subsequent pregnancies (1,2). A retrospective Japanese study reported that 37% of women with placenta previa after previous cesarean sections developed placenta increta or percreta and had an increased risk of fatal maternal complications (3). In China, the incidence of placenta previa coexisting with placenta accreta spectrum (PAS) has risen rapidly as a consequence of the increase in cesarean delivery rates and the implementation of a two-child policy over the past decade (4). PAS includes placenta creta, placenta increta, and placenta percreta (5). Patients with placenta previa with increta or percreta require cesarean section, during which blood loss can be severe. Therefore, there is an increased risk of related fatal maternal complications, such as disseminated intravascular coagulation, multisystem organ failure, and death (6,7). Emergency hysterectomy is an essential measure to control severe intraoperative hemorrhage and reduce complications; however, it results in inevitable infertility (8,9). In China, hysterectomy is not widely accepted by patients, who usually demand preservation of their uterus. Complications of placenta increta and percreta during cesarean section can be severe and even fatal. For patients with placenta increta or percreta, the risk prediction of adverse events and hemostatic measures are the primary points in clinical diagnosis and treatment. Ultrasonography and magnetic resonance imaging (MRI) are considered to be the primary methods for the diagnosis of placenta increta and percreta, owing to their accuracy in detecting placental invasion (10,11). However, there are no system-recognized evaluation methods to predict intraoperative massive blood loss due to placenta increta or percreta (5). Therefore, the primary aim of the present study was to determine high-risk factors and to develop and validate risk prediction models for intraoperative massive blood loss during cesarean section in patients with placenta previa with placenta increta or percreta. We present the following article in accordance with the TRIPOD reporting checklist (available at http://dx.doi.org/10.21037/atm-20-5160).

Methods

Researchers may contact the corresponding authors for the data within the article for future analysis.

Study design and participants

The present study was a retrospective analysis of all placenta increta and percreta patients who attended or were referred to the Department of Obstetrics, Qilu Hospital of Shandong University, Jinan, China, with a subsequent terminated pregnancy between January 2016 and June 2019. A total of 179 patients who were admitted from January 2016 to December 2017 were selected and allocated to the development group, while 81 patients who were admitted between January 2018 and June 2019 were allocated to the validation group. All patients were diagnosed with placenta increta or percreta intraoperatively, either by an obstetrician or by histopathology. When no penetration of the placenta close to the serous layer and no or little vascularity of the uterine serosa-bladder wall interface were observed, the case was classified as creta. When increased vascularity of the uterine serosa-bladder wall interface, myometrial thinning of the anterior wall, and penetration of the placenta close to the serous layer were observed, the case was classified as increta. Based on this, when the placenta penetrated through the uterine surface, even invading into the bladder or other organs, the case was classified as percreta. The inclusion criteria were as follows: (I) a history of cesarean section; (II) availability of B-scan ultrasonography examination; (III) singleton pregnancy; and (IV) patient request for fertility preservation. The exclusion criteria were preoperative coagulation disorders or blood system diseases. The flowchart for patient selection is shown in .
Figure 1

Flowchart of included patients. ROC, receiver operating characteristic.

Flowchart of included patients. ROC, receiver operating characteristic. The characteristics of patients prior to delivery were collected from medical records. Preoperative clinical features included age at delivery, gestational age, gravidity, parity, number of previous cesarean sections, history of dilatation and curettage of the uterus, gestational diabetes mellitus, hemoglobin, placenta previa classification, retroplacental myometrial thickness, vascular lacunae within the placenta, hypervascularity of the uterine-placental margin, irregularity of the uterine-bladder interface, hypervascularity of the uterine serosa-bladder wall interface, hypervascularity of the cervix, and emergency cesarean section. Surgical characteristics included preoperative balloon placement in the abdominal aorta (BPAA), B-Lynch suture, ligation of the ascending branch of the uterine artery, and tourniquet binding of the lower uterine segment. No uniform criteria exist to define adverse pregnancy outcomes in placenta increta or percreta (12,13). In the present study, we selected intraoperative blood loss ≥2,500 mL for each case as the major adverse maternal endpoint. Patients were followed up for 6 months after delivery. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethical Committee of Qilu Hospital in Jinan, Shandong Province, China (No. 2019013) and individual consent for this retrospective analysis was waived.

Statistical analysis

Baseline characteristics of patients were expressed as descriptive statistics, and values are shown as medians (interquartile ranges) or n (%). Continuous data were compared using the Mann-Whitney U-test, and classified data were analyzed with Pearson’s χ2-test or Fisher’s exact χ2-test. Univariate logistic regression analysis was used to identify predictors associated with adverse maternal outcomes. Variables with P<0.10 were enrolled in the multivariate logistic regression analysis. Results are presented as odds ratios, 95% confidence intervals (CIs), and P value factors. Based on the regression coefficients of independent variables, individualized nomogram prediction models were established. Discriminative power and calibration of high-risk factors were tested through receiver operating characteristic (ROC) curve and calibration curve analyses. Decision curve analysis was applied to assess the performance of the predictive models. SPSS version 24.0 (IBM, Armonk, New York, USA), and R software version 3.6.2 (http://cran.r-project.org) were used for the statistical analyses.

Results

Baseline characteristics of women with placenta increta or percreta are presented in . A total of 260 pregnant women diagnosed with placenta increta or percreta were included in our research. All patients had previously undergone at least one cesarean section and placenta previa. Twenty-eight (10.8%) patients had an emergency cesarean section because of fetal distress, uterine contraction, and vaginal bleeding. Sixty-six (25.4%) patients selected BPAA before cesarean section. Seventy-one (27.3%) patients experienced massive bleeding during cesarean section (≥2,500 mL), and hysterectomy was performed in 8 (3.1%) patients. The most common surgical complication was bladder repair (n=20, 7.7%). None of the patients died during the study.
Table 1

Baseline characteristics

CharacteristicsDevelopment group (n=179)Validation group (n=81)P value
Preoperative characteristics
   Age at delivery (years)32 [29–36]35 [31–37]0.002
   Gravidity3 [3–4]4 [3–5]0.154
   Parity1 [1–1]1 [1–2]<0.001
   History of dilatation and curettage of uterus1 [0–2]1 [0–1]0.867
   Previous caesarean section0.003
    ≤1142 (79.3)50 (61.7)
    >137 (20.7)31 (38.3)
   Preoperative HGB level (g/L)0.456
    <10066 (36.9)26 (32.1)
    ≥100113 (63.1)55 (67.9)
   Gestational age (days)255 [244–260]253 [245–261]0.769
   Obstetric complications
    Preeclampsia2 (1.1)4 (4.9)0.009
    Gestational diabetes mellitus17 (9.5)11 (13.6)0.325
   Placenta previa classification0.118
    Marginal placenta previa22 (12.3)17 (21.0)
    Partial placenta previa4 (2.2)3 (3.7)
    Complete placenta previa153 (85.5)61 (75.3)
   Prenatal ultrasound results
    Retroplacental myometrial thickness <1 mm127 (70.9)55 (67.9)0.619
    Vascular lacunae within the placenta107 (59.8)48 (59.3)0.937
    Hypervascularity of uterine-placental margin127 (70.9)48 (59.3)0.063
    Irregularity of uterine-bladder interface26 (14.5)33 (40.7)<0.001
    Hypervascularity of the uterine serosa-bladder wall interface43 (24.0)34 (42.0)0.003
    Hypervascularity of cervix19 (10.6)13 (16.0)0.217
   Type of PAS0.058
    Placenta increta169 (94.4)71 (87.7)
    Placenta percreta10 (5.6)10 (12.3)
   Emergency cesarean section21 (11.7)7 (8.6)0.457
Surgical characteristics
   Total operation time (min)90 [73–120]98 [70–124]0.635
   Length of hospital (days)11 [8–17]10 [8–20.5]0.912
   Postoperative Length of hospital (days)5 [4–7]5 [4–7]0.718
   Intraoperative blood loss1,200 [800–2,500]1,800 [1,000–2,500]0.050
   Intraoperative blood loss ≥2,500 mL45 (25.1)26 (32.1)0.243
   Units of PRBC transfused4 [4–8]6 [4–8]0.232
   Preoperative BPAA46 (25.7)20 (24.7)0.863
   B-Lynch suture36 (20.1)40 (49.4)<0.001
   Ligation of ascending branch of uterine artery32 (17.9)15 (18.5)0.901
   Tourniquet binding the lower uterine segment23 (12.8)18 (22.2)0.055
   Hysterectomy4 (2.2)4 (4.9)0.261
   Bladder repair10 (5.6)10 (12.3)0.058
   Systemic infections4 (2.2)1 (1.2)1.000
   Thrombotic complications
    Pulmonary embolism1 (0.6)0 (0.0)1.000
    DVT or thrombotic requiring therapy0 (0.0)1 (1.2)0.312
   DIC2 (1.1)1 (1.2)1.000
   ICU2 (1.1)2 (2.5)0.591

Values are median [interquartile range] or n (%). HGB, hemoglobin; PAS, placenta accreta spectrum; PRBC, packed red blood cells; BPAA, balloon placement of abdominal aorta; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; ICU, intensive care unit.

Values are median [interquartile range] or n (%). HGB, hemoglobin; PAS, placenta accreta spectrum; PRBC, packed red blood cells; BPAA, balloon placement of abdominal aorta; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; ICU, intensive care unit. The results of the univariable logistic regression analysis are presented in . Risk factors according to multivariate logistic regressions are shown in . Four independent risk factors were included in prediction model A: vascular lacunae within the placenta, hypervascularity of the uterine-placental margin, hypervascularity of the cervix, and emergency cesarean section (P<0.05). After the addition of cesarean section characteristics, six independent risk factors were included in prediction model B: vascular lacunae within the placenta, hypervascularity of the uterine-placental margin, hypervascularity of the uterine serosa-bladder wall interface, hypervascularity of the cervix, emergency cesarean section, and no preoperative BPAA (P<0.05). The nomogram prediction models are shown in .
Table 2

Univariate analysis in the development group

CharacteristicsOR (95% CI)P value
Preoperative characteristics
   Age (years)1.00 (0.90–1.08)0.947
   Gestational age (days)1.00 (0.98–1.00)0.187
   Caesarean section >11.59 (0.72–3.50)0.253
   History of dilatation and curettage of uterus0.87 (0.63–1.21)0.412
   GDM2.28 (0.81–6.41)0.117
   HGB <100 g/L1.05 (0.52–2.12)0.884
   Placenta previa classification1.01 (0.60–1.67)0.986
   Retroplacental myometrial thinning <1 mm1.36 (0.63–2.95)0.433
   Vascular lacunae within the placenta2.58 (1.21–5.52)0.014
   Hypervascularity of uterine-placental margin2.26 (0.97–5.26)0.058
   Irregularity of uterine-bladder interface1.12 (0.44–2.86)0.821
   Hypervascularity of the uterine serosa-bladder wall interface1.89 (0.90–3.99)0.094
   Hypervascularity of cervix2.42 (0.91–6.46)0.078
   Emergency cesarean section4.01 (1.57–10.23)0.004
Surgical characteristics
   No preoperative BPAA4.68 (1.57−13.91)0.006
   B-Lynch suture0.84 (0.37–1.92)0.683
   Ligation of ascending branch of uterine artery0.83 (0.35–1.95)0.668
   Tourniquet binding the lower uterine segment0.47 (0.19–1.17)0.103

GDM, gestational diabetes mellitus; HGB, hemoglobin; BPAA, balloon placement of abdominal aorta; OR, odds ratio; CI, confidence interval.

Table 3

Multivariate logistic regression models in the development group

VariablesRegression coefficientsOR (95% CI)P value
Model A
   Vascular lacunae within the placenta1.2923.64 (1.45–9.14)0.006
   Hypervascularity of uterine-placental margin1.2303.42 (1.26–9.27)0.016
   Hypervascularity of cervix1.1553.17 (1.08–9.33)0.036
   Emergency cesarean section2.37610.76 (3.31–34.91)<0.001
Model B
   Vascular lacunae within the placenta1.4444.24 (1.97–21.66)0.005
   Hypervascularity of uterine-placental margin1.8776.53 (1.55–11.61)0.002
   Hypervascularity of the uterine serosa-bladder wall interface1.3373.81 (1.23–11.77)0.020
   Hypervascularity of cervix1.5844.87 (1.35–17.62)0.016
   Emergency cesarean section2.44911.57 (3.22–41.67)<0.001
   No preoperative BPAA2.83016.95 (4.05–70.92)<0.001

BPAA, balloon placement of abdominal aorta; OR, odds ratio; CI, confidence interval.

Figure 2

Nomograms to predict the probability of intraoperative massive blood loss in the patient with placenta increta or percreta. The nomogram can be applied by following procedures: (I) obtain the points corresponding to each predictor, (II) the sum of the points is recorded as the total score, and (III) the predicted risk corresponding to the total score is the probability of intraoperative blood loss ≥2,500 mL in placenta increta and percreta.

GDM, gestational diabetes mellitus; HGB, hemoglobin; BPAA, balloon placement of abdominal aorta; OR, odds ratio; CI, confidence interval. BPAA, balloon placement of abdominal aorta; OR, odds ratio; CI, confidence interval. Nomograms to predict the probability of intraoperative massive blood loss in the patient with placenta increta or percreta. The nomogram can be applied by following procedures: (I) obtain the points corresponding to each predictor, (II) the sum of the points is recorded as the total score, and (III) the predicted risk corresponding to the total score is the probability of intraoperative blood loss ≥2,500 mL in placenta increta and percreta. In the development group, the area under the ROC curve (AUC) of model A was 0.732 (95% CI: 0.655–0.809), the sensitivity was 84.4%, and the specificity was 48.5%. The AUC of model B was 0.839 (95% CI: 0.781–0.897), the sensitivity was 91.1%, and the specificity was 67.2%. The difference between the AUCs of models A and B was 0.107 (Z=3.786, P<0.001) (). In the validation group, the AUC of model A was 0.736 (95% CI: 0.626–0.845), the sensitivity was 76.9%, and the specificity was 60%. The AUC of model B was 0.829 (95% CI: 0.742–0.916), the sensitivity was 84.6%, and the specificity was 69.1%. The difference between the AUCs of models A and B was 0.093 (Z=2.653, P=0.007) (). Therefore, model B had a better discriminative power than model A.
Figure 3

ROC curves and calibration plots. (A) Development group, AUC of model A is 0.732 (95% CI: 0.655–0.809), AUC of model B is 0.839 (95% CI: 0.781–0.897), P value is less than 0.001 (A vs. B); (B) validation group, AUC of model A is 0.736 (95% CI: 0.626–0.845), AUC of model B is 0.829 (95% CI: 0.742–0.916), P value is 0.007 (A vs. B); (C) model A in development group, (D) model B in development group, (E) model A in validation group, (F) model B in validation group. Calibration curves were applied to evaluate the calibration of the models. The horizontal axis is the predicted probability provided by the model, and the vertical axis is the observed incidence of intraoperative blood loss ≥2,500 mL. The 45-degree line is the actual probability. When the prediction probability of model is closer to the 45-dgree line, the prediction model has better calibration power. When the solid line is below the 45-dgree line, the prediction probability provided by the model is higher than the actual probability (overprediction); if the solid line is above the 45-dgree line, the prediction probability provided by the model is lower than the actual probability (underprediction).

ROC curves and calibration plots. (A) Development group, AUC of model A is 0.732 (95% CI: 0.655–0.809), AUC of model B is 0.839 (95% CI: 0.781–0.897), P value is less than 0.001 (A vs. B); (B) validation group, AUC of model A is 0.736 (95% CI: 0.626–0.845), AUC of model B is 0.829 (95% CI: 0.742–0.916), P value is 0.007 (A vs. B); (C) model A in development group, (D) model B in development group, (E) model A in validation group, (F) model B in validation group. Calibration curves were applied to evaluate the calibration of the models. The horizontal axis is the predicted probability provided by the model, and the vertical axis is the observed incidence of intraoperative blood loss ≥2,500 mL. The 45-degree line is the actual probability. When the prediction probability of model is closer to the 45-dgree line, the prediction model has better calibration power. When the solid line is below the 45-dgree line, the prediction probability provided by the model is higher than the actual probability (overprediction); if the solid line is above the 45-dgree line, the prediction probability provided by the model is lower than the actual probability (underprediction). The calibration curves of both models in the development group are shown in , and the slope was 1.00 and 1.00, respectively. The calibration curves in the validation group are shown in , and the slope was 0.72 and 0.68 in models A and B, respectively. When the slope was closer to 1.00, the prediction model had better calibration power. Decision curves were used to evaluate the clinical utility of models A and B. In both the training and validation groups, model B (black) showed a higher area under the decision curve than model A (red) ().
Figure 4

Decision curves. (A) Development group, (B) validation group. Draw the decision curve with the net benefit as vertical axis and the threshold probability as horizontal axis. The solid black line represents the net benefit when all patients are considered as not developing outcome (intraoperative blood loss ≥2,500 mL). The solid grey line represents the net benefit when all patients are considered as developing outcome. The preferred model is the model with the highest net benefit.

Decision curves. (A) Development group, (B) validation group. Draw the decision curve with the net benefit as vertical axis and the threshold probability as horizontal axis. The solid black line represents the net benefit when all patients are considered as not developing outcome (intraoperative blood loss ≥2,500 mL). The solid grey line represents the net benefit when all patients are considered as developing outcome. The preferred model is the model with the highest net benefit.

Discussion

A retrospective study of 260 pregnant women with placenta increta or percreta who underwent cesarean section was constructed to establish two nomograms for predicting intraoperative massive blood loss. The model combining preoperative and surgical features showed better discrimination compared with the model combining preoperative features. The main findings of the present study were: (I) emergency cesarean section and ultrasound findings, including vascular lacunae within the placenta, hypervascularity of the uterine-placental margin, hypervascularity of the uterine serosa-bladder wall interface, and hypervascularity of the cervix are independently associated with massive blood loss; and (II) preoperative BPAA is a protective factor for massive blood loss. Therefore, preoperative ultrasound signs can help to identify high-risk patients early, and management during cesarean section can reduce intraoperative blood loss in patients with placenta increta or percreta. The combined model can be applied by obstetricians to enhance prenatal assessments of placenta increta or percreta patients, and to select the safest surgical treatment for these patients. With the rising rates of cesarean section worldwide, from 6.7% in 1990 to 12.4% in 2010, many studies have reported an increased incidence of placenta previa or placenta increta with massive hemorrhage (14,15). Wright et al. found that previous cesarean deliveries had no association with massive blood loss (≥5,000 mL) (16). In the present study, the 75th quantile of intraoperative blood loss was 2,500 mL, and 71 (27.3%) patients experienced this outcome; therefore, intraoperative blood loss ≥2,500 mL was taken as the adverse outcome. More than one previous cesarean section was not found to be a risk factor of intraoperative blood loss ≥2,500 mL in the multivariate logistic regression analysis. Blood transfusion support is challenging, for the average blood loss during a delivery complicated by PAS was from 2 to 5 L (17). Compared with placenta creta or increta, patients with placenta percreta are more likely to require additional blood products and have a higher incidence of urological complications, including ureteric injury and cystotomy (18). Therefore, preoperative evaluation of placenta increta or percreta is crucial for predicting peripartum outcomes (6). Ultrasound and MRI are first-line methods for the diagnosis of PAS, with reported sensitivity and specificity values of 97% and 97% for ultrasound and 94.4% and 84% for MRI, respectively (10,11). Recently, Rac et al. and Bourgioti et al. established prediction models according to ultrasound and MRI findings to evaluate the type of placental invasion (19,20). In their study, Collins et al. summarized the ultrasound signs used to diagnose PAS (21). However, no specific ultrasound sign or combination of ultrasound signs to determine the depth of placental villous implantation or to accurately distinguish PAS classifications has been found (22). This may be due to the various clinical diagnostic criteria of PAS. A detailed diagnosis of PAS is often not reported when specimens are not available for histopathological examination in cases of placental creta or conservative treatment (23). In the present study, we combined ultrasound signs with other clinical characteristics of patients to establish prediction models. MRI features were not included in the analysis for the majority of patients who had not been evaluated by MRI. Ultrasound signs of placenta increta or percreta patients were found to be associated with intraoperative blood loss in model B, improving the early identification of high-risk patients prior to surgery. During surgery, drugs, sutures, vascular occlusion, and interventional radiology are often used to manage and prevent severe blood loss in patients with PAS (24-26). A few prospective and retrospective studies have evaluated the role of prophylactic BPAA to mitigate bleeding and avoid hysterectomy during surgery (26-28). In the present study, surgical features were included to establish model B, and we found that BPAA can significantly diminish the amount of intraoperative blood loss. Complications are a significant concern of preoperative BPAA. Wu et al. reported that 2 of 230 cases developed vein thrombosis of the lower limbs (27). Zhu et al. reported one case that had abdominal aortic dissection complications (28). Injury of the vascular endothelium and occlusion-related thrombotic complications raise significant concerns for the safety of BPAA. In the present study, only one patient developed deep vein thrombosis of the lower limb after BPAA. Current studies have not sufficiently demonstrated the risk-benefit ratio of the use of abdominal aorta occlusion with balloon placement. Therefore, more well-designed studies are needed. In the present study, gestational age was not found to be associated with massive blood loss; however, emergency cesarean section is a high-risk factor, and preoperative preparation is essential for these patients. As most patients request that their uterus not be removed, at our medical center, safe management to avoid massive blood loss is prioritized, including ultrasound screening and monitoring, hemostatic measures, and transfusion support. A strength of the present study was the prenatal assessment strategy to identify high-risk factors associated with maternal adverse events in placenta previa with increta or percreta. A limitation of the study was that we only analyzed placenta increta or percreta in PAS, which usually causes intraoperative massive blood loss, and placenta creta was not included. In further research, we will explore all types of PAS, including placenta creta. If verified prospectively, our findings could be used to develop a specific procedure to identify and standardize the management of placenta increta or percreta patients, and ultimately improve pregnancy outcomes.

Conclusions

Risk prediction models established with preoperative and surgical characteristics can assist obstetricians to identify high-risk patients, develop treatment strategies to reduce the incidence of intraoperative massive blood loss, and further improve the prognosis of patients with placenta previa with increta or percreta. The article’s supplementary files as
  28 in total

1.  Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta.

Authors:  Louis Marcellin; Pierre Delorme; Marie Pierre Bonnet; Gilles Grange; Gilles Kayem; Vassilis Tsatsaris; François Goffinet
Journal:  Am J Obstet Gynecol       Date:  2018-05-05       Impact factor: 8.661

2.  Prophylactic use of resuscitative endovascular balloon occlusion of the aorta in women with abnormal placentation: A systematic review, meta-analysis, and case series.

Authors:  Carlos A Ordoñez; Ramiro Manzano-Nunez; Michael W Parra; Todd E Rasmussen; Albaro J Nieto; Juan P Herrera-Escobar; Paula Fernandez; Maria P Naranjo; Alberto F García; Javier A Carvajal; Juan M Burgos; Fernando Rodriguez; Maria F Escobar-Vidarte
Journal:  J Trauma Acute Care Surg       Date:  2018-05       Impact factor: 3.313

3.  Ultrasound predictors of placental invasion: the Placenta Accreta Index.

Authors:  Martha W F Rac; Jodi S Dashe; C Edward Wells; Elysia Moschos; Donald D McIntire; Diane M Twickler
Journal:  Am J Obstet Gynecol       Date:  2014-10-18       Impact factor: 8.661

4.  Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a.

Authors:  Erm Jauniaux; Z Alfirevic; A G Bhide; M A Belfort; G J Burton; S L Collins; S Dornan; D Jurkovic; G Kayem; J Kingdom; R Silver; L Sentilhes
Journal:  BJOG       Date:  2018-09-27       Impact factor: 6.531

5.  FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology.

Authors:  Eric Jauniaux; Frederic Chantraine; Robert M Silver; Jens Langhoff-Roos
Journal:  Int J Gynaecol Obstet       Date:  2018-03       Impact factor: 3.561

6.  FIGO consensus guidelines on placenta accreta spectrum disorders: Introduction.

Authors:  Eric Jauniaux; Diogo Ayres-de-Campos
Journal:  Int J Gynaecol Obstet       Date:  2018-03       Impact factor: 3.561

7.  Predictors of massive blood loss in women with placenta accreta.

Authors:  Jason D Wright; Shai Pri-Paz; Thomas J Herzog; Monjri Shah; Clarissa Bonanno; Sharyn N Lewin; Lynn L Simpson; Sreedhar Gaddipati; Xuming Sun; Mary E D'Alton; Patricia Devine
Journal:  Am J Obstet Gynecol       Date:  2011-03-17       Impact factor: 8.661

Review 8.  Abnormal Placentation: Placenta Previa, Vasa Previa, and Placenta Accreta.

Authors:  Robert M Silver
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

9.  The Increasing Trend in Caesarean Section Rates: Global, Regional and National Estimates: 1990-2014.

Authors:  Ana Pilar Betrán; Jianfeng Ye; Anne-Beth Moller; Jun Zhang; A Metin Gülmezoglu; Maria Regina Torloni
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

10.  Maternal 'near miss' collection at an Australian tertiary maternity hospital.

Authors:  Skandarupan Jayaratnam; Sonia Kua; Caroline deCosta; Richard Franklin
Journal:  BMC Pregnancy Childbirth       Date:  2018-06-11       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.